[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f9xqxhzXmbf22n4d_uo0pHJvFlqmjs8zLNotyjn_0q9M":8,"$fLYmh1t-mcrBfKNlI2th0-4JuuHygmQXsqNafMZjSRTA":55,"$fprjzKtNpxseFe8T2czIFsFgNbWY1czVpfoRxBkm8ePs":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},48303,868816,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//AlGR54AfQXCNBVdRQuF4F8mZ83YfHTaP.png","陈柳波","浙江大学医学院附属第二医院","肿瘤科","住院医师",56,0,"💡肠癌肝转移治疗新方向：KRAS G12V突变相关药物安全用药全指南","","https://ystcdn.venuertc.com/venue/AI/9e88de25-79e6-4a74-9daa-f94d3645d119.jpg","\u003Cdiv class=\"drug-material-container\">\n    \u003Ch1 id=\"material_title\" class=\"drug-material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n        💡肠癌肝转移治疗新方向：KRAS G12V突变相关药物安全用药全指南\n    \u003C/h1>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fafc 10%, #e6ecef 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">一、KRAS突变相关药物简介及临床应用背景\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            说到肠癌肝转移的药物选择，KRAS基因突变（尤其是G12V型）一直是大家十分关心的话题。像贝伐珠单抗、FOLFIRI方案（包括伊立替康和氟尿嘧啶等）等药物，目前在临床已被广泛应用于KRAS突变的相关治疗中。本文会用7个关键问题，带大家打通从药理作用到安全用药的每个细节，帮助您和家人远离不必要的用药风险。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #eef6f9 0%, #f9f9fc 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">二、药物作用机制是什么？\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            KRAS G12V突变相关药物多为化疗药和靶向抗肿瘤药物，作用机制各有不同。\u003Cbr>\n            \u003Cstrong>1. 贝伐珠单抗（Bevacizumab）：\u003C/strong>这是一种靶向血管生成的单克隆抗体，通过阻断肿瘤生长所需的新生血管形成，间接抑制肿瘤扩展\u003Csup>[1]\u003C/sup>。\u003Cbr>\n            \u003Cstrong>2. FOLFIRI方案（伊立替康+氟尿嘧啶+亚叶酸钙）：\u003C/strong>伊立替康是一种拓扑异构酶I抑制剂，能中断肿瘤细胞分裂。氟尿嘧啶和亚叶酸钙组合，则会干扰DNA合成，加强对肿瘤细胞的杀灭\u003Csup>[2]\u003C/sup>。\u003Cbr>\n            \u003Cstrong>特别提醒：\u003C/strong>KRAS G12V突变患者通常对表皮生长因子受体（EGFR）抑制剂这类生物制剂效果不明显，临床上会优先考虑上述药物。\n        \u003C/p>\n    \u003C/div>\n\n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8f6f2 0%, #f3f8f7 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">三、正确的服药时间与方法\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            这类药物大多由专业医生在医院内静脉输注使用，自行服用的可能性不大，但家庭照护者和患者了解正确流程也非常重要。\u003Cbr>\n            \u003Cstrong>贝伐珠单抗：\u003C/strong>通常每2周或3周静脉滴注一次，每次滴注持续时间不少于30-90分钟。\u003Cbr>\n            \u003Cstrong>伊立替康及FOLFIRI相关药物：\u003C/strong>同样采用静脉给药方式，通常每2周一疗程，具体滴注时间和混合顺序需严格遵医嘱。\u003Cbr>\n            \u003Cstrong>氟尿嘧啶：\u003C/strong>可采用长时间（如48小时）静脉泵注，也可以部分短时注射，与亚叶酸钙联合时要注意先后顺序。\u003Cbr>\n            \u003Cspan style=\"color: #c9802c;\">\u003Cstrong>正确做法：\u003C/strong>\u003C/span>每种药物注射方案和剂量必须由专业医护人员制定。对于患者和家属，关注输注过程是否平稳、留意输注部位及体感异常，发现不适需立即反馈医护人员。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #eef9f5 0%, #f7f7fc 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">四、剂型选择与用药规格\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            相关药物多为注射剂型，口服制剂选择有限。\u003Cbr>\n            \u003Cstrong>（1）贝伐珠单抗：\u003C/strong>溶液为100mg/4ml或400mg/16ml安瓿，需专用设备稀释静脉滴注。\u003Cbr>\n            \u003Cstrong>（2）伊立替康：\u003C/strong>常见规格为40mg/2ml或100mg/5ml安瓿。\u003Cbr>\n            \u003Cstrong>（3）氟尿嘧啶：\u003C/strong>50mg/ml注射液为主，也有其他浓度包装。\u003Cbr>\n            无论哪种剂型，家庭不宜自行处理开瓶、分装或稀释等环节。抗肿瘤药多具刺激性，不可与食物、饮品混合口服；如皮肤、粘膜接触，必须及时用大量清水冲洗。\n        \u003C/p>\n    \u003C/div>\n\n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fafc 10%, #ece9ee 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">五、常见药物相互作用及预防方法\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            \u003Cspan style=\"font-size: 1.1em;\">🔗\u003C/span> 药物合用，相互作用不可忽视。\u003Cbr>\n            \u003Cstrong>1. 化疗药与胰岛素：\u003C/strong>化疗药物（如伊立替康、氟尿嘧啶）可影响血糖波动，与门冬胰岛素等降糖药一起使用时，应密切监测血糖。\u003Cbr>\n            \u003Cstrong>2. 化疗药与抗凝药：\u003C/strong>氟尿嘧啶、伊立替康与口服抗凝药合用时可增加出血风险。\u003Cbr>\n            \u003Cstrong>3. 贝伐珠单抗：\u003C/strong>与非甾体抗炎药（如布洛芬）同用时出血风险加大。\u003Cbr>\n            \u003Cstrong>4. CYP酶相互作用：\u003C/strong>伊立替康主要经肝脏CYP3A4代谢，含大剂量葡萄柚汁、圣约翰草等草药会影响药效或毒性。\u003Cbr>\n            \u003Cspan style=\"color: #19777d;\">正确做法：\u003C/span> 合并用药前务必主动告知医生目前所用药物清单，尤其是所有口服或注射药品和保健品，避免自行加减。\n        \u003C/p>\n    \u003C/div>\n\n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f6f9f2 0%, #ecf2f7 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">六、特殊人群用药调整及禁忌症\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            某些人使用这类药物时需要特别警惕：\u003Cbr>\n            \u003Cstrong>1. 肝肾功能不全者：\u003C/strong>伊立替康、氟尿嘧啶等药物主要经肝肾代谢，功能不全时应调整剂量或慎用。\u003Cbr>\n            \u003Cstrong>2. 糖尿病患者：\u003C/strong>贝伐珠单抗和部分化疗药可干扰血糖控制，需随时观察低血糖或高血糖风险。\u003Cbr>\n            \u003Cstrong>3. 孕妇及哺乳期妇女：\u003C/strong>此类化疗药和靶向药在孕期、哺乳期原则上禁用或需权衡利弊。\u003Cbr>\n            \u003Cstrong>4. 已知过敏史或免疫抑制状态：\u003C/strong>使用贝伐珠单抗、伊立替康前需仔细询问药物及蛋白制品过敏情况，避免诱发严重反应。\u003Cbr>\n            \u003Cspan style=\"color: #a84846;\">禁忌：\u003C/span>严重过敏、活动性出血、严重肝肾功能受损者禁用。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fafc 10%, #f9ece2 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">七、常见不良反应与应对措施\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            \u003Cspan style=\"font-size: 1.1em;\">⚠️\u003C/span> 不良反应并不少见，关注异常变化有助于早期干预：\u003Cbr>\n            \u003Cstrong>贝伐珠单抗：\u003C/strong>高血压、出血和蛋白尿发生率增加，有数据显示蛋白尿发生率为21-38%\u003Csup>[3]\u003C/sup>。部分患者可有静脉栓塞风险。\u003Cbr>\n            \u003Cstrong>伊立替康：\u003C/strong>常有腹泻（早期和晚期两型），脱发、白细胞减少等。腹泻发生率可达60%以上。\u003Cbr>\n            \u003Cstrong>氟尿嘧啶：\u003C/strong>可见手足综合征、口腔炎、恶心呕吐以及骨髓抑制等副作用。\u003Cbr>\n            \u003Cspan style=\"color: #266760;\">出现不良反应时：\u003C/span>轻度不适可以告知医护观察，若有严重腹泻、持续高热、大量出血等异常，及时联系就诊，不宜拖延。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f6f9fb 0%, #eef6f2 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">八、存储条件与有效期管理\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            \u003Cstrong>贝伐珠单抗/伊立替康/氟尿嘧啶等注射剂：\u003C/strong>通常需保存在2-8℃冰箱冷藏，避免冷冻。\u003Cbr>\n            \u003Cstrong>正确做法：\u003C/strong>仅限医院药房专业冷链保存和调配；家中如偶有备用，应远离儿童、阳光直射及家庭厨房等高温场所。\u003Cbr>\n            \u003Cstrong>过期处理：\u003C/strong>严禁自行丢弃或使用，需交予医疗机构按规定处置。\n        \u003C/p>\n    \u003C/div>\n  \n\n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fafc 10%, #eceff4 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">九、漏服和过量处理原则\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            由于本类药物全部为医院静脉输注，如果错过用药通常应尽快与主管医师联系，切勿自行补药或随意调节剂量。\u003Cbr>\n            \u003Cstrong>过量风险：\u003C/strong>高剂量化疗药和靶向药有较大毒性，如超量注射可造成严重感染、骨髓抑制甚至危及生命。\u003Cbr>\n            \u003Cspan style=\"color: #5b4a2e;\">正确做法：\u003C/span>一旦怀疑药量异常，立即暂停后续用药并由专业团队评估处理。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f1f7f9 10%, #fcfbfa 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十、用药实例分享\u003C/h2>\n        \u003Cul class=\"drug-case-list\">\n            \u003Cli>有一位患者在贝伐珠单抗和FOLFIRI方案合用过程中，因手足综合征未耐受呋奎替尼，及时停药并调整其他药物后，副反应明显缓解。\u003C/li>\n            \u003Cli>临床上使用伊立替康期间，定期验血监测能提前发现白细胞减少和骨髓抑制，帮助及时减量避免感染。\u003C/li>\n            \u003Cli>对于合并糖尿病的患者，化疗期间每周监测2-3次血糖波动，配合调整胰岛素剂量，提高用药安全性。\u003C/li>\n        \u003C/ul>\n    \u003C/div>\n\n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f8fafc 10%, #f7f3e9 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">十一、用药指引小结\u003C/h2>\n        \u003Cp class=\"drug-material-paragraph\">\n            总结来看，贝伐珠单抗、伊立替康、氟尿嘧啶等在KRAS G12V突变相关治疗中应用广泛，安全用药关键是严格遵医嘱输注，关注不良反应，主动监测相互作用和并发症风险。特别要为特殊体质及合并基础疾病的患者个体化调整方案。遇到任何不适或异常，不可“扛一扛”，而要迅速就医。\u003Cbr>\n            合理用药、积极配合、规范储存与及时反馈，是保证这些药物发挥最佳疗效并降低风险的主要原则。\n        \u003C/p>\n    \u003C/div>\n  \n    \u003Cdiv class=\"drug-section\" style=\"background: linear-gradient(90deg, #f4f6fb 0%, #f6f3d6 100%); margin-bottom: 32px;\">\n        \u003Ch2 class=\"drug-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献\u003C/h2>\n        \u003Col class=\"drug-reference-list\">\n            \u003Cli>Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 2004, 350(23):2335-2342. \u003Ca href=\"https://www.nejm.org/doi/full/10.1056/NEJMoa032691\" target=\"_blank\">[NEJM]\u003C/a>\u003C/li>\n            \u003Cli>Rothenberg ML, et al. Superiority of irinotecan, fluorouracil, and leucovorin combination therapy compared with fluorouracil and leucovorin alone in patients with previously treated metastatic colorectal cancer. \u003Cem>Journal of Clinical Oncology\u003C/em>, 1999, 17(8):2186-2194. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/10458256/\" target=\"_blank\">[PubMed]\u003C/a>\u003C/li>\n            \u003Cli>Kabbinavar FF, et al. Overall survival rates improve with bevacizumab. \u003Cem>Journal of Clinical Oncology\u003C/em>, 2003, 21(6):1236-1245. \u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12637471/\" target=\"_blank\">[PubMed]\u003C/a>\u003C/li>\n        \u003C/ol>\n    \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.drug-material-container {\n    max-width: 850px;\n    margin: 32px auto 32px auto;\n    padding: 32px 28px;\n    background: #f7fafc;\n    border-radius: 14px;\n    box-shadow: 0 2px 12px rgba(182,193,212,0.16);\n    font-family: 'Segoe UI', 'PingFang SC', 'Hiragino Sans GB', 'Arial', sans-serif;\n    font-size: 18px;\n    color: #23272e;\n}\n.drug-material-title {\n    font-size: 2.1em;\n    font-weight: 700;\n    color: #263a52;\n    letter-spacing: 1.2px;\n    text-align: center;\n    margin-bottom: 44px;\n    margin-top: 0;\n    line-height: 1.3;\n}\n.drug-section {\n    padding: 28px 30px 24px 30px;\n    border-radius: 12px;\n    margin-bottom: 36px;\n    box-sizing: border-box;\n    position: relative;\n}\n.drug-section-title {\n    font-size: 1.3em;\n    color: #285176;\n    font-weight: 600;\n    margin-bottom: 18px;\n    letter-spacing: 1px;\n    background: none;\n    border: none;\n    padding: 0;\n}\n.drug-material-paragraph {\n    font-size: 1em;\n    color: #373737;\n    line-height: 1.88;\n    margin-bottom: 0;\n    margin-top: 0;\n}\n.drug-case-list {\n    padding-left: 1.5em;\n    margin-top: 0;\n    margin-bottom: 0;\n}\n.drug-case-list li {\n    margin-bottom: 13px;\n    line-height: 1.65;\n    position: relative;\n    font-size: 1em;\n}\n.drug-reference-list {\n    margin-top: 0;\n    padding-left: 1.4em;\n}\n.drug-reference-list li {\n    font-size: 0.97em;\n    margin-bottom: 10px;\n    line-height: 1.65;\n}\n@media screen and (max-width: 650px) {\n    .drug-material-container {\n        padding: 12px 4px;\n        font-size: 15px;\n    }\n    .drug-section {\n        padding: 14px 9px 16px 9px;\n    }\n    .drug-section-title {\n        font-size: 1.13em;\n    }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"drug-material-container\">\n    \u003Ch1 id=\"material_title\" class=\"drug-material-title\" style=",516,"2025-07-11 10:49:26","肠癌, KRAS突变, 贝伐珠单抗, 伊立替康, 安全用药, 化疗药物, 肝转移, 药物作用机制, 不良反应","本文深入剖析KRAS G12V突变相关药物的临床应用、安全用药指南，帮助患者及家属有效减少用药风险，确保治疗效果。","2025-07-13 14:09:49",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]